Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma

NCT01826448 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01826448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01826448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Terminated
Start date
November 5, 2013
Completion date
September 22, 2014
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii or stage iv metastatic melanoma that has not been previously treated with a selective braf inhibitor, v600-mutated braf metastatic melanoma, v600-mutated braf unresectable melanoma